TY  - JOUR
AU  - Tzikas, Stergios
AU  - Schlak, Dennis
AU  - Sopova, Kateryna
AU  - Gatsiou, Aikaterini
AU  - Stakos, Dimitrios
AU  - Stamatelopoulos, Kimon
AU  - Stellos, Konstantinos
AU  - Laske, Christoph
TI  - Increased myeloperoxidase plasma levels in patients with Alzheimer's disease.
JO  - Journal of Alzheimer's disease
VL  - 39
IS  - 3
SN  - 1875-8908
CY  - Amsterdam
PB  - IOS Press
M1  - DZNE-2020-03585
SP  - 557-564
PY  - 2014
AB  - Increasing evidence supports the role of cardiovascular risk factors in the development of Alzheimer’s disease (AD).Objective:In the present pilot study, we investigated plasma concentrations of myeloperoxidase (MPO) and its possible association with plasma amyloid-β (Aβ)1-42/1-40 ratio in AD patients and elderly healthy controls.Methods:The study sample included 28 AD patients and 27 elderly individuals with a normal cognitive status as a control group. The Mini-Mental Status Examination was used to determine the global cognition. MPO, Aβ1-40, and Aβ1-42 plasma concentrations were measured by enzyme linked immunoabsorbent assays.Results:AD patients showed significantly higher plasma concentrations of MPO in comparison to healthy elderly controls (AD versus healthy elderly controls (mean ± SD): 132.8 ± 114.8 ng/mL versus 55.0 ± 42.6 ng/mL; p = 0.002). MPO plasma concentrations showed a significant positive correlation in the whole sample with the presence of AD (ρ = 0.428, p < 0.001) and its stage (ρ = 0.331; p = 0.013) as well as with plasma concentrations of Aβ1-42 (ρ = 0.406; p = 0.004) and Aβ1-42/1-40 ratio (ρ = 0.354; p = 0.013). In a binary logistic regression model, plasma MPO concentrations were independently associated with the presence of AD (p = 0.014).Conclusion:AD patients showed significantly increased plasma levels of MPO, which could be an important molecular link between atherosclerosis and AD. Further studies should evaluate whether MPO may also be a useful biomarker and potential new treatment target in AD.
KW  - Aged
KW  - Aged, 80 and over
KW  - Alzheimer Disease: blood
KW  - Amyloid beta-Peptides: blood
KW  - Female
KW  - Humans
KW  - Immunoenzyme Techniques
KW  - Logistic Models
KW  - Male
KW  - Mental Status Schedule
KW  - Neuropsychological Tests
KW  - Peptide Fragments: blood
KW  - Peroxidase: blood
KW  - ROC Curve
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - Peptide Fragments (NLM Chemicals)
KW  - amyloid beta-protein (1-40) (NLM Chemicals)
KW  - amyloid beta-protein (1-42) (NLM Chemicals)
KW  - Peroxidase (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:24217274
DO  - DOI:10.3233/JAD-131469
UR  - https://pub.dzne.de/record/137263
ER  -